

CURRICULUM VITAE

SABINO DE PLACIDO

***Professore Ordinario di Oncologia Medica
Università di Napoli Federico II***

2015

Indice

Curriculum Vitae

Note Biografiche	pag. 3
Posizione Accademica	pag. 3
Curriculum degli Studi	pag. 3
Ruoli Accademici	pag. 4
Ruoli Clinico-Assistenziali	pag. 4
Incarichi Didattici	pag. 5
Incarichi Scientifici	pag. 5

Elenco Pubblicazioni

Pubblicazioni a Severo Controllo Redazionale	pag. 7
Testi Universitari	pag. 33

NOTE BIOGRAFICHE

COGNOME E NOME: De Placido Sabino
NAZIONALITA': Italiana
DATA E LUOGO DI NASCITA: 15.5.1953 - Grottaminarda (AV)

POSIZIONE ACCADEMICA

Settore Concorsuale

dal 28/10/2011 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA

Settore Scientifico Disciplinare

dal 14/03/2001 MED/06 - ONCOLOGIA MEDICA

Qualifica Professore Ordinario

Anzianità nel ruolo di Professore di I fascia

01/11/2000

Sede Universitaria

Università degli Studi di NAPOLI "Federico II"

Dipartimento

Dipartimento di MEDICINA CLINICA E CHIRURGIA
Via S. Pansini 5, 80131, Napoli

CURRICULUM DEGLI STUDI

- Ott. 1977 Laurea in Medicina e Chirurgia con voti 110 e lode/110,
Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II"
- Nov. 1982 Specializzazione in "Medicina Interna" con voti 50 e lode/50, Facoltà di
Medicina e Chirurgia, Università di Napoli "Federico II"
- Lug. 1985 Specializzazione in "Oncologia" con voti 70 e lode/70,
Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II"

RUOLI ACCADEMICI

- 1991 - 2000 Professore Associato di Oncologia Medica della Facoltà di Medicina, Università
"Federico II" Napoli
- Da Nov. 2000 Professore Ordinario di Oncologia Medica della Facoltà di Medicina, Università
"Federico II" Napoli
- 2006 - 2013 Direttore della Scuola di Specializzazione di Oncologia, Facoltà di Medicina,
Università "Federico II" Napoli
- 2011 - 2012 Direttore del Dipartimento Scientifico di Endocrinologia ed Oncologia
Molecolare e Clinica - Università di Napoli Federico II
- Da Mag. 2013 Senatore Accademico, Università di Napoli Federico II
- Da Nov. 2013 Coordinatore della Commissione di Coordinamento Didattico del Corso di
Laurea Magistrale in Medicina e Chirurgia

RUOLI CLINICO-ASSISTENZIALI

- 1996-1997 Primario dell'Area Funzionale 'Terapie Oncologiche Speciali' del Dipartimento
Assistenziale di Oncologia ed Endocrinologia Clinica, Azienda Universitaria
Policlinico, Università di Napoli Federico II
- 1997 - 2013 Direttore di struttura complessa 'Terapie Oncologiche Speciali' del
Dipartimento Assistenziale di Endocrinologia ed Oncologia Molecolare e
Clinica - Azienda Ospedaliera Universitaria, Università di Napoli Federico II
- dal 2013 Direttore di struttura complessa 'Oncologia Medica' del Dipartimento
Assistenziale Integrato di Medicina Clinica Azienda Ospedaliera

Universitaria, Università di Napoli Federico II

INCARICHI DIDATTICI

- 1) Membro della Rete Europea, detta "Inner Circle ECTS" (European Credit Transfer System), riservata solo a tre Facoltà mediche Italiane per selezione della Commissione Europea dopo sottomissione di progetto; essa è stata la prima a prevedere il trasferimento completo di crediti accademici degli studenti in ambito europeo.
- 2) Delegato della Facoltà di Medicina e Chirurgia nella Commissione SOCRATES-ERASMUS di Ateneo dell'Università Federico II, per la pianificazione della mobilità di studenti e docenti nell'ambito dei Paesi Europei. In questa sua attività il Prof. De Placido ha contribuito a realizzare una rete con circa 32 università europee tra le maggiori, che permette a circa 60 studenti ogni anno di realizzare un periodo di studio all'estero.
- 3) Presidente della Commissione LLP-ERASMUS
- 4) Coordinatore e Delegato per la Facoltà di Medicina e Chirurgia di Napoli Federico II per:
 - Programma di Cooperazione Interuniversitario (PIC)(contratto n. ICP-I-1288/12) tra Paesi dell'Unione Europea per il Programma ERASMUS
 - Progetti Europei Comuni (PEC) (contratto n. JEP-4733-I) con Paesi di Est Europa per il Programma TEMPUS.
- 5) Coordinatore del Corso integrato di "Oncologia Clinica" Facoltà di Medicina e Chirurgia, Università Federico II, Napoli
- 6) Dottorato Internazionale: Partecipazione al Collegio del Dottorato "Oncologia ed Endocrinologia Molecolare" Anni: 2008, 2009, 2010, 2011.

RUOLI E INCARICHI SCIENTIFICI

- 1) Presidente del Collegio degli Oncologi Medici Universitari (COMU), eletto da docenti e ricercatori di tutte le Università italiane;
- 2) Membro eletto e Vicepresidente del Comitato Etico di Ateneo, Università di Napoli Federico II;
- 3) Presidente Consorzio "Oncotech", che coordina sperimentazioni cliniche cui partecipano circa 100 qualificate prestigiose Istituzioni oncologiche nazionali;
- 4) Membro della Commissione Nazionale Ricerca Sanitaria (CNRS) del Ministero della Salute, per nomina e decreto del Ministro della Salute (26-7-2007 / 26-7-2010);
- 5) Membro del Consiglio Direttivo del Consorzio Interuniversitario per la Bio-Oncologia (CINBO), ente pubblico posto sotto la vigilanza del Ministero dell'Università e della Ricerca (MUR) e che raggruppa 13 Università Italiane con scopo istituzionale di svolgere attività di formazione e ricerca avanzata nel settore dell'oncologia (2007-2013);
- 6) Coordinatore delle attività del Centro di riferimento Regionale per la Prevenzione Oncologica (CRPO), nell'ambito di un programma di intervento di sanità pubblica di prevenzione secondaria del carcinoma mammario e del carcinoma della cervice uterina;
- 7) Membro del Comitato Tecnico Scientifico (CTS) dell'Istituto Nazionale Tumori di Napoli "Fondazione Pascale" (2008-2012).
- 8) Promotore e coordinatore di attività di ricerca del Gruppo Italiano Mammella (GIM), che coordina studi clinici controllati sulla terapia innovativa del carcinoma mammario in ambito nazionale;
- 9) Nomina di "Esperto" della ESF (European Science Foundation) per il programma europeo di "European Survey on Bio-medical Research Infrastructures (Bio-med RI) nel campo della ricerca oncologica (Strasburgo, 2003)

Elenco pubblicazioni:

- 2015 Di Lorenzo G, Buonerba C, De Placido S. Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. *Anticancer Drugs*. 2015 Feb;26(2):236-9. doi: 10.1097/CAD. PMID:25340916
- Arpino G, De Placido S, De Angelis C. Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. *Anticancer Drugs*. 2015 Jan;26(1):117-22. doi:10.1097/CAD. PMID:25115342
- 2014 Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev*. 2014 Dec 8. S0305-7372(14)00193-5. doi: 10.1016/j.ctrv.2014.12.001.
- Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A. Weekly docetaxel vs CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomised phase 3 ELDA trial. *Ann Oncol*. 2014 Dec 8. pii: mdu564. [Epub ahead of print] PMID:25488686 Select item 25405197
- De Stefano A, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Di Pietro F, Pepe S, De Placido S, Carlomagno C. Bevacizumab maintenance in metastatic colorectal cancer: How long? *World J Clin Cases*. 2014 Nov 16;2(11):717-23. doi:10.12998/wjcc.v2.i11.717. PMID:25405197
- De Placido S, Pronzato P. Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us? *Future Oncol*. 2014 Sep 18:1-7. PMID:25230682
- D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. *Br J Cancer*. 2014 Sep 9;111(6):1168-7 doi: 10.1038/bjc.2014.421.
- De Placido S, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, Izzo M, Policastro T, Di Lorenzo G. Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. *World J Clin Cases*. 2014 Jun 16;2(6):228-31 doi:10.12998/wjcc.v2.i6.228. PMID:24945013

Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy*. 2014 Mar;6(3):349-60. doi: 10.2217/imt.13.169.PMID:24762078

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaoli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. *Ann Oncol*. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146.

Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D. Targeting bone metastatic cancer: Role of the mTOR pathway. *Biochim Biophys Acta*. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009.

Di Lorenzo G, De Placido S. Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new? *Future Oncol*. 2014 Apr;10(5):845-50 doi: 10.2217/fon.13.269.

Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, Troncone G, De Stefano A, Pepe S, De Placido S, D'Incalci M, Marchini S, Carlomagno C. Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. *Biomed Res Int*. 2014;2014:840921. doi: 10.1155/2014/840921.

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. *Breast Cancer Res*. 2014 Sep 16;16(5):440. doi: 10.1186/s13058-014-0440-8. PMID:25223629

De Stefano A, Moretto R, Bucci L, Pepe S, Romano FJ, Cella AC, Attademo L, Rosanova M, De Falco S, Fiore G, Raimondo L, De Placido S, Carlomagno C. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when and for whom? *CLINICAL COLORECTAL CANCER*;Sep;13(3):185-91

Formisano L, Nappi I, Rosa R, Marciano R, D'Amato C, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. *Breast Cancer Res*. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650

Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpati GD, Ferro M, Cobelli OD, De Placido S, Aieta M, Imbimbo C, Di Lorenzo G. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. *Future Oncol*. 2014 Jun;10(8):1353-60. doi: 10.2217/fon.14.71. PMID: 25052746

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

LANCET; Jun 21;383(9935):2127-35; doi: 10.1016/S0140-6736(14)60488-8.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutati V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIg) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

THE LANCET ONCOLOGY; Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X.

Criscitello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast*. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. PMID: 24314620

D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. *Br J Cancer*. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241.

2013 Pizzi C, Arpino G, Acampora G, Aiello N, DE Rosa A, Diaferia I, DI Nunzio A, Fragna G, Franco A, Russo M, Sansone F, Scarpati C, Spinuso A, Arpino G, Luce A, Tommasielli G, Caraglia M, DE Placido S. Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. *Mol Clin Oncol*. 726-732. PMID:24649236

De Angelis C, Milano M, Gargiulo P, Stanzione B, Forestieri V, Lauria R, Pensabene M, D'Arco F, De Placido S, Arpino G. Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. *Tumori*. doi: 10.1700/1334.14822.PMID:24158083

Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. *Biomed Res Int*. doi: 10.1155/2013/852839. Review.PMID:24063014

Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. *Gruppo Italiano Mammella.Oncologist*. doi: 10.1634/theoncologist.2013-0222. PMID:23939283

Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudio G, Terracciano D, Di Trollo R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R.J Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. *Transl Med*. doi: 10.1186/1479-5876-11-161.PMID:23819610

Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. *Future Oncol*. doi: 10.2217/fo.13.39.PMID:23718309

Rescigno P, Di Trollo R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G. Non-AIDS-related Kaposi's sarcoma: A single-institution experience. *World J Clin Oncol*.doi: 10.5306/wjco.v4.i2.52.PMID:23696963

Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalomogna R, Galli A, Del Mastro L. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. *Breast*. doi: 10.1016/j.breast.2013.03.012. Epub 2013 May 1.PMID:23642526

Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. *BMC Cancer*. doi: 10.1186/1471-2407-13-164.PMID:23537313

Di Lorenzo G, Buonerba C, Gaudio G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trollo R, Ascierto PA, De Placido S, Perdonà S, Franco R. EGFR mutational status in penile cancer. *Expert Opin Ther Targets*. doi: 10.1517/14728222.2013.783571.PMID:23517177

Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F. EMPACT syndrome associated with phenobarbital. *Dermatitis*. doi: 10.1097/DER.0b013e31827ede32.PMID:23340399

Di Lorenzo G, Di Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Peg-filgrastim and cabazitaxel in prostate cancer patients. *Anticancer Drugs*. doi: 10.1097/CAD.0b013e32835a56bc.PMID:23044721

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutati V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. *LANCET ONCOLOGY*;

Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R. Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and

angiogenic activity of renal cell carcinoma. ONCOIMMUNOLOGY, vol. 2

De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, pace L, De Placido S, Salvatore M, Del Vecchio S. Combined Imaging With 18F-FDG-PET/CT and 111 In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors. CLINICAL NUCLEAR MEDICINE

Clavarezza M, Bordinaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, De Mastrol L; Gruppo Italiano Mammella.ONCOLOGIST, vol. 18, pag. 924-25

Moretto R, Raimondo L, De Stefano A, Cella CA, Matano E, De Placido S, Carlomagno C. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. ANTICANCER DRUGS, vol. 24, pag. 980-5

Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G. Potentia value of Gleason scoere in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. FUTURE ONCOLOGY, vol. 9, pag. 889-97

Gentile I, De Stefano A, Di Flumeri G, Buonomo AR, Carlomagno C, Morisco F, De Placido S, Borgia G. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a cae report. IN VIVO, vol, 27, pag. 527-9

Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudio G, Terracciano D, Di Trollo R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11

Rescigno P, Di Trollo R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G. Non-AIDS-related Kaposi's sarcoma: A single-institution experience. WORLD JOURNAL OF CLINICAL ONCOLOGY, vol. 4, pag. 52-7

Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. BREAST, vol. 22, pag. 470-5

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E. An Italian cost- effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional pacliatxel for metastatic breast cancer patients: the COSTANza study. CLINICOECONOMICS OUTCOMES RESEARCH

Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, veneziani BM, De Placido S, Bianco R, Tortora G. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumor growth and angiogenesis. BRITISH JOURNAL CANCER, vol. 108, pag. 1616-23

Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC CANCER.

Arpino G, Generali D, Sapino A, Lucia DM, Frassoldati A, De Laurentiis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L. Gene expression profiling in breast cancer: A clinical perspective. BREAST,

Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F. EMPACT syndrome associated with phenobarbital. DERMATITIS, vol. 24, pag. 37-39

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, veneziani BM, Troncone G, De Placido S, Bianco R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. CLINICAL CANCER RESEARCH, vol. 19, pag. 138-147

Di Lorenzo G, Buonerba C, Gaudio G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trollo R, Ascierto P, De Placido S, Perdonà S, Franco R. EGFR mutational status in penile cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 17, pag. 501-5

De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del vecchio S. Combined imaging with 18F-FDG-PET/CT and 111 In-labeled octreotide SPECT for evaluation of thymic epithelial tumors. CLINICAL NUCLEAR MEDICINE, vol. 38, pag. 354-8.

Di Lorenzo G, D'Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Peg- filgrastim and cabazitaxel in prostate cancer patients. ANTICANCER DRUGS, vol. 24, p. 84-89

2012 Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. Review.PMID:23043326

Malgieri S, Feliciano S, Bosso D, Federico P, Palmieri G, De Placido S, Di Lorenzo G, Buonerba C. Non-small cell lung cancer: from targeted therapy to tailored therapy. *Expert Opin Pharmacother.* 2012 Sep;13(13):1817-9. doi: 10.1517/14656566.2012.707645.PMID:2280370

Di Lorenzo G, De Placido S, Buonerba C. Second-line treatment for renal cell cancer. *Br J Cancer.* doi: 10.1038/bjc.2011.611. PMID:22333706

Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. *CURRENT DRUG TARGETS*, vol. 13, p. 1676-1686

Malgieri S, Feliciano S, Bosso D, Federico P, Palmieri G, De Placido S, Di Lorenzo G, Buonerba C. Non-small cell lung cancer: from targeted therapy to tailored therapy. *EXPERT OPINION ON PHARMACOTHERAPY*, vol.13, p. 1817-1819

Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, palmieri G, Sonpavde G, Mirone V, De Placido S. Cisplatin and 5-fluorouracil in inoperabile stage IV squamos cell carcinoma of the penis.*BJU INTERNATIONAL*

Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G. (in stampa). KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer . *BRITISH JOURNAL OF CANCER*, pag. 1-6,

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh Vijay K, D'Incalci M, De Placido S, Pepe S. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer. *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*, vol. 83, pag. 1113-1119,

Grünwald V., Karakiewicz P., Bavbek S.E, Miller K., Machiels J.P., Lee S.H., Larkin J., Bono P., Rha S.Y., Castellano D., Blank C.U., Knox J.J., Hawkins R., Anak O., Rosamilia M., Booth J., Pirota N., Bodrogi I., REACT Study Group, included, De Placido S. (2012). An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy. . *EUROPEAN JOURNAL OF CANCER*, p. 324-332, ISSN: 0959-8049

Rescigno P., Matano E., Raimondo L., Mainolfi C., Fedeico P., Buonerba C., Di Trollo R., D'Aniello C., Damiano V., Palmieri G., De Placido S., Di Lorenzo G. (2012). Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. *ANTI-CANCER DRUGS*, p. 573-577, ISSN: 0959-4973

Leccia F, Nardone A, Corvigno S, Del Vecchio L, De Placido S, Salvatore F, Veneziani BM . Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous

myoepithelial phenotypes . CYTOMETRY. PART A, ISSN: 1552-4922, doi: 10.1002/cyto.a.22095

Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, Caolo G, Mottolese M, Botti G, Terrenato I, Vici P, Serpico D, Giordano A, D'Aiuto G, Crispo A, Montella M, Capurso G, Delle Fave G, Fuhrman B, Botti C, De Placido S.. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. ANNALS OF ONCOLOGY, vol. 23, pag. 1838-1845

Veneziani BM., De Placido S. Issues of banking breast cancer cells to generate mammospheres.. CELL AND TISSUE BANKING, p. 1-6, ISSN: 1389-9333, doi: 10.1007/s10561-012-9320-6

Di Lorenzo G, De Placido S, Buonerba C. Second-line treatment for renal cell cancer. BRITISH JOURNAL OF CANCER, p. 617-618, ISSN: 1532-1827

2011 Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, De Placido S, Tortora G. Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 2, pag. 449-455,

Di Lorenzo G., Casciano R., Malangone E., Buonerba C., Sherman S., Willet J., Wang X., Liu Z., De Placido S. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples . EXPERT OPINION ON PHARMACOTHERAPY, pag. 1491-1497, ISSN: 1465-6566

Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Puzsai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.. BREAST CANCER RESEARCH AND TREATMENT, vol. 129, pag. 451-458

De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 68, pag. 1207-1213.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.. BREAST CANCER RESEARCH, vol. 13, pag. R67-R76,

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.. ANNALS OF ONCOLOGY, p. Epub ahead of print, ISSN: 0923-7534, doi: 10.1093/annonc/mdr434

Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta M.T, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini C.A, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a syntetic review. TUMORI, pag. 690-692,

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. LANCET, vol. 378, p. 1707-1716,

Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI, ATHENA Study Group, De Placido S. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients ANNALS OF ONCOLOGY, pag. 595-602,

Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V. Imatinib mesylate in thymic epithelial malignancies.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, pag. 309-315,

Campiglio M., Bufalino R., Sandri M., Ferri E., Aiello R.A., De Matteis A., Mottolese M., De Placido S., Querzoli P., Jirillo A., Bottini A., Fantini M., Bonetti A., Pedani F., Mauri M., Molino A., Ferro A., Pupa S.M., Sasso M., Ménard S., Balsari A., Tagliabue E. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study . BREAST CANCER RESEARCH AND TREATMENT, pag. 147-154,

Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, Cognetti F, Dondi D, Venturini M. Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience . EUROPEAN JOURNAL OF CANCER, pag. 642-647

Di Lorenzo G., Federico P., Buonerba C., Longo N., Carteni G., Autorino R., Perdonà S., Ferro M., Rescigno P., D'Aniello C., Matano E., Altieri V., Palmieri G., Imbimbo C., De Placido S., Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. . EUROPEAN UROLOGY, pag. 1280-1284

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients . CANCER CHEMOTHERAPY AND

PHARMACOLOGY, pag. 1455-1461

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.. LANCET, vol. 378, pag. 771-784,

2010 Buonerba C, Di Lorenzo G, Marinelli A, Federico P., Palmieri G., Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH. A comprehensive outlook on intracerebral therapy of malignant gliomas . CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 80, pag. 54-68

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V. A third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. EUROPEAN UROLOGY, vol. 58, pag. 906-911,

Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, De Stefano Alfonso, D'Armiento F P, De Placido S. Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors.. EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 1, pag. 611-617

Capri G, Chang J, Chen Sc, Conte P, Cwierka K, Jerusalem G, Jiang Z, Jhonston S, Kaufman B, Link J, Ro J, Schutte J, Oliva C, Parikh R, Preston A, Roselund J, Selzer M, Zembryki D, De Placido S (2010). An open-label expanded assess study of lapatinib and capecitabina in patients with HER2 - overexpressing locally advanced or metastatic breast cancer. ANNALS OF ONCOLOGY, pag. 474-480

Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? JOURNAL OF NEURO-ONCOLOGY, vol. 100, pag. 311-319,

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Strenberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies . DRUGS, pag. 983-1000

Terracciano D, Mazzeola C, Di Carlo A, Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido S, Macchia V. Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. ONCOLOGY REPORTS, vol. 24, pag. 213-217,

Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Meroca MC, De Placido S, Palmieri G. Efficacy of rituximab in gastric diffuse large B cell Lymphoma patients.. WORLD JOURNAL OF GASTROENTEROLOGY, pag. 2526-2530

Colantuoni M, Matano E, Alfieri S, De Placido S, Carlomagno C. Guillain Barrè syndrome associated with gastric cancer: paraneoplastic syndrome or immunological disorder? WORLD JOURNAL OF ONCOLOGY, vol. 1, pag.247-249

Carlomagno C, Insabato L, Bifulco G, De Placido S, Lauria R. Ovarian metastasis following gallbladder carcinoma: a case report. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, pag. 219-221

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C., McGale P., Taylor C., Wang Y., Clarke M., Davies C., Peto R., Bijker N., Solin L., Darby S., De Placido S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast . JOURNAL OF THE NATIONAL CANCER INSTITUTE, pag. 162-177,

Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, Carlomagno C, De Placido S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.. JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS, vol. 2010, pag. 162-167

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Carteni G. Phase II Study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU INTERNATIONAL, pag. 234-239

Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M, De Placido S. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. ONCOLOGY, vol. 78, pag.369-375

Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, Milella M, Ceribelli A, Montella L, Merola C, Del Prete S, Vergaglio M, De Placido S, Di Lorenzo G. Preliminary result of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). . ANNALS OF ONCOLOGY, pag. 1168-1172,

Duffy S, Jackson TL, Lansdown M, Phillips K, Wells M, Clack G, Bianco AR, ATAC Trialists' Group, De Placido S. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol. . JOURNAL OF OBSTETRICS AND GYNAECOLOGY, pag. 596-604

- De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.. CANCER TREATMENT REVIEWS, pag 80-86,
- 2009 Di Lorenzo G, Carteni G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. . ANTI-CANCER DRUGS, vol. Anti-cancer Drugs, pag. 277-280
- Nardone A, Cavaliere C, Corvigno, S, Limite G, De Placido S, Veneziani BM. A banking strategy toward customized therapy in breast cancer. CELL AND TISSUE BANKING, vol. 10, pag. 301-308,
- Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis . ANNALS OF ONCOLOGY, pag. 1535-1542
- Montagna E, Canello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 63, pag. 275-280
- Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, De Placido S. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer . ONCOLOGY, pag. 23-37
- Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento M, De Placido S. (2009). Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study. ANNALS OF ONCOLOGY, vol. 20, pag. 906-912
- Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S (2009). Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. CANCER, pag. 517-523
- 2008 Di Lorenzo G, Kreuter A, Di Trollo R, Guarini A, Romano C , Montesarchio V, Brockmeyer N, De Placido S, Bower M, Dezube Br. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 128, pag. 1578-1580

Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.. LANCET, vol. 371, pag. 29-40,

Perdonà S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L, Silvestro G, Farella A, De Placido S, Di Lorenzo G. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. CANCER, vol. 112, pag. 75-83,

Di Lorenzo G, Figg W, Fossa S, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. EUROPEAN UROLOGY, vol. 54, pag. 1089-1094

Cancello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. BREAST CANCER RESEARCH, vol. 10, pag. 1-8

Di Lorenzo G, Di Trolio R, Montesarchio V, Palmieri G, Nappa P, Delfino M, De Placido S, Dezube BJ. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. . CANCER, vol. 112, pag. 1147-1152

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. JOURNAL OF CLINICAL ONCOLOGY, vol. 26, pag. 44-53

Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, De Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 66, pag. 171-180,

2007 Di Lorenzo G, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, De Stefano A, Esposito V, De Placido S, Montesarchio V. (2007). Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. WORLD JOURNAL OF GASTROENTEROLOGY, vol. 13, pag. 6553-6557,

Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, G. Tortora, Figg Wd, De Placido S (2007). Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. EUROPEAN UROLOGY, vol. 52, pag. 1020-1027

Di Lorenzo G, Autorino R, Figg W, De Placido S Hormone-refractory prostate cancer: where are we going?. DRUGS, vol. 67, pag. 1109-1124,

Veneziani BM, Criniti V, Cavaliere C, Corvigno S, Nardone A, Picarelli S, Tortora G, Ciardiello F, Limite G, De Placido S. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.. MOLECULAR CANCER THERAPEUTICS, vol. 6, pag. 3091-3100

Di Lorenzo G, Konstantinopoulos P, Pantanowitz L, Di Trollo R, De Placido S, Dezube B. Management of AIDS-related Kaposi's sarcoma. LANCET ONCOLOGY, vol. 8, pag. 167-176

Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D' Armiento M, De Placido S, Conti P, Di Lorenzo G. Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 20, pag. 765-770

Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, Russo A, Benincasa G, D'armiento M, Altieri V, De Placido S .Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. UROLOGY, vol. 69, pag. 347-351

Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, Russo A, Benincasa G, D'Armiento M, Altieri V, De Placido S. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.. UROLOGY, vol. Urology pag. 347-51

Di Lorenzo G, De Placido S. Re: Perabo FGE and Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol 2007; 18: 835-843. ANNALS OF ONCOLOGY, vol. 18, pag. 1118-1127

Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla Er, Agrawal S, Ciardiello F, G. Tortora. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, pag. 12468-12473

Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer. A phase I clinical trial.. CANCER BIOLOGY & THERAPY, vol. 6, pag. 313-317

- Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne K, Schiff R. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 99, pag. 694-705
- 2006 Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani Bm, Fontanini G, Eckhardt SG, De Placido S, Tortora G, Ciardiello F . Antitumor activity of the combination of cetuximab, an anti-egfr blocking monoclonal antibody and zd6474, an inhibitor of vegfr and egfr tyrosine kinases. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 208, pag. 344-353
- Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, vol. 29, p. 85-89
- Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 19, pag. 11-34
- Damiano V, Caputo R, Bianco R, Darmiento F, Leonardi A, De Placido S, Bianco Ar, Agrawal S, Ciardiello F, G. Tortora. Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors.CANCER RESEARCH, vol. 12, pag. 577-583
- Ciardiello F, Troiani T, Caputo F, De Laurentiis M, G. Tortora, Palmieri G, De Vita F, Diadema Mr, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.. BRITISH JOURNAL OF CANCER, vol. 94, pag.1604-1609
- Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Vernaglia Lombardi A, Manzione L, Carteni G, Nardi M, Danese S, Valerio MR, De Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F . Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC CANCER, vol. 6, pag. 5
- Di Trollo R, Di Lorenzo G, Delfino M,. De Placido S . Role of pegylated liposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 19, pag. 253-263
- Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L, Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F (2006). Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. ANNALS OF ONCOLOGY, vol. 17, pag. 1529-1532

2005 De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'agostino D, Caputo F, Cancellato G, Montagna E, Malorni, L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *CLINICAL CANCER RESEARCH*, vol. 11, pag. 4741-4748

De Vita F, Orditura M, Matano E, Bianco R., Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. (2005). A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.. *BRITISH JOURNAL OF CANCER*, vol. 92, pag. 1644-1649,

De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'aprile M, Pistillucci G, Farris A, Sarobba Mg, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferrau F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco Ar, GOCSI COOPERATIVE GROUP. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.. *BRITISH JOURNAL OF CANCER*, vol. 92, pag. 467-474

Massarelli E, Liu D, Lee J, El-Naggar AK, Lo Muzio L, Staibano S, De, Placido S, Myers JN, Papadimitrakopoulou VA (2005). Akt activation correlates with adverse outcome in tongue cancer.. *CANCER*, vol. 104, pag. 2430-2436

Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco Ar, S. De Placido, Ciardiello F, Tortora G. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.. *CLINICAL CANCER RESEARCH*, vol. 11, pag. 5639-5644

Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repettos L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo. Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. *TUMORI*, vol. 91, pag. 373-379

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S .Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.. *LANCET*, vol. 365, pag. 1687-1717

Perdona S, Autorino R, De Placido S, D'armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco Ar, Di Lorenzo G. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. *LANCET ONCOLOGY*, vol. 6, pag. 295-300

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 97, pag. 1254-1261

Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'armiento M, Tortora G, De Rosa G, D'armiento M, De Sio M, Bianco Ar, F. D'armiento. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. PROSTATE CANCER AND PROSTATIC DISEASES, vol. 8, pag. 54-59

Di Lorenzo G, Perdonà S, De Placido S, D'armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. JOURNAL OF UROLOGY, vol. 174, pag. 2197-2203

Di Lorenzo G, Autorino R, Perdon S, De Placido S. Management of gynaecomastia in patients with prostate cancer: a systematic review. LANCET ONCOLOGY, vol. 6, pag. 972-979

De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello Gp, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini, M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco A. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. BRITISH JOURNAL OF CANCER, vol. 93, pag. 896-904

Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M, Perdon S, De Fortuna E, Salzano L, De Placido S, D'Armiento M. Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer.. MINERVA UROLOGICA E NEFROLOGICA, vol. 57, pag. 319-324

Di Lorenzo G, Di Trollo R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides.. BRITISH JOURNAL OF DERMATOLOGY, vol. 153, pag. 183-185

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hocht-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group, De Laurentiis M, De Placido S, Carlomagno C. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. LANCET, vol. 365, pag. 60-62,

De Laurentiis M, Canello G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, Caputo F, Accurso A, De Placido S (2005). Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. ANNALS OF ONCOLOGY, vol. 16, pag. iv7-iv13

De Sio M, D'Armiento M, Di Lorenzo G, Damiano R, Perdona S., De Placido S, Autorino R. The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know?. *BJU INTERNATIONAL*, vol. 96, pag. 977-983

Danova M, Rosti G, De Placido S, Bencardino K, Venturini M. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists. *ONCOLOGY REPORTS*, vol. 14, pag. 1405-1412,

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani Bm, Bianco Ar, De Placido S, Ciardiello F, G. Tortora (2005). Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. *ENDOCRINE-RELATED CANCER*, vol. 12, pag. 1051-1058

2004 Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, S. De Placido, Bianco Ar, Tortora G (2004). Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.. *CLINICAL CANCER RESEARCH*, vol. 10, pag. 784-793

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco Ar, Ciardiello F, Tortora G. Combined targeting of egfr and mdm2 by gefitinib and antisense mdm2 cooperatively inhibit hormone-independent prostate cancer. *CLINICAL CANCER RESEARCH*, vol. 10, pag. 4858-4864

Di Lorenzo G, Autorino R, D'Armiento FP, Mignogna C, De Laurentiis M, De Sio M, D'Armiento M, Damiano R, Vecchio G, De Placido S. Expression of proto-oncogene c-kit in high risk prostate cancer. *EUROPEAN JOURNAL OF SURGICAL ONCOLOGY*, vol. 30, pag. 987-992

Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'armiento M, Bianco AR, De Placido S. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. *JAPANESE JOURNAL OF CLINICAL ONCOLOGY*, vol. 34, pag. 747-750

Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'armiento M, Bianco AR, De Placido S. HER-2/neu receptor in prostate cancer development and progression to androgen independence. *TUMORI*, vol. 90, pag. 163-170

Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C. Insurance for independent cancer trials. *ANNALS OF ONCOLOGY*, vol. 15, pag. 1722-1723

Barba M, Mccann S, Schünemann H, Stranges S, Fuhrman B, De Placido S, Carruba G, Freudenheim L, Trevisan M, Russell M, Nochajski T, Muti P. Lifetime total and beverage specific--alcohol intake and prostate cancer risk: a case-control study. *NUTRITION JOURNAL*, vol. 3, pag. 23

Ippolito AM, De Laurentiis M, La G, Eleuteri A, Tagliaferri R, De Placido S, Vigneri R, Belfiore A. Neural network analysis for evaluating cancer risk in thyroid nodules with an indeterminate diagnosis at aspiration cytology: identification of a low-risk subgroup. *THYROID*, vol. 14, pag. 1065-1071

Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A, De Placido S. Quality of Life of Postmenopausal the Women in the Arimidex, Tamoxifen, alone or in combination (ATAC) Adjuvant breast Cancer Trial. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 22, pag. 4261-4271

Scambia SD, Di Vagno G, Naglieri G, Lombardi E, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febraro A, De Matteis A, Gasparini G, Valerio Mr, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. (2004). Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study *JOURNAL OF ONCOLOGY*, vol. 22, pag. 2635-2642

Di Lorenzo G, Pizza C, Autorino R, De Laurentiis M, Marano O, D'Alessio A, Canello G, Altieri V, Tortora G, Perdonà S, Bianco AR, De Placido S. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. *EUROPEAN*, vol. 46, pag. 712-716

2003 Eleuteri A, Tagliaferri R, Milano L, S. De Placido, De Laurentiis M. A Novel Neural Network-Based Survival Analysis Model. A novel neural network-based survival analysis model.. *NEURAL NETWORKS*, vol. 16, pag. 855-864

De Sio M, Autorino R, Di Lorenzo G, Damiano R, Cosentino L, De Placido S, D'Armiento M. Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma.. *UROLOGIA INTERNATIONALIS*, vol. 71, pag. 361-367

Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group, De Laurentiis m, De Placido S, Carlomagno C (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.. *CANCER*, vol. 98, pag. 1802-1810

Tortora G, Caputo R, Damiano V, Caputo R, Melisi D, Bianco R, Fontanini G, Veneziani Bm, De Placido S, Bianco Ar, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 ('Iressa') and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect. *CLINICAL CANCER RESEARCH*, pag. 1231-1232

- Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.. *CLINICAL CANCER RESEARCH*, vol. 9, pag. 1566-1572
- Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F. Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity. *CLINICAL CANCER RESEARCH*, pag. 866-871
- Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G . Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.. *EXPERT OPINION ON EMERGING DRUGS*, vol. 8, pag. 501-514
- Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.. *ONCOLOGY REPORTS*, vol. 10, pag. 399-404
- Minenkova O, Pucci A, Pavoni E, De Tomassi A, Fortugno P, Gargano N, Cianfriglia M, Barca S, De Placido S, Martignetti A, Felici F, Cortese R, Monaci P. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. *INTERNATIONAL JOURNAL OF CANCER*, vol. 106, pag. 534-544
- Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S. (2003). Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. *TUMORI*, vol. 89, pag. 349-360
- Autorino R, Di Lorenzo G, Damiano R, De Placido S, D'Armiento M. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.. *UROLOGIA INTERNATIONALIS*, vol. 70, pag. 1-14
- De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Pettinato G, Petrella G, Bianco AR. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.. *CLINICAL CANCER RESEARCH*, vol. 9, pag. 1039-1046
- 2002 De Placido S. Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trials. *LANCET*, vol. 359, pag. 2131-2139

- Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group, De Laurentiis M, De Placido S, Carlomagno C. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.. LANCET, vol. 359, pag. 2131-2139
- Di Lorenzo G, Tortora G, D'Armineto FP, De Rosa G, Staibano S, Autorino R, Darmiento M, De Laurentiis M, S. De Placido, Catalano G, Bianco AR, Ciardiello F. Expression of Epidermal Growth Factor Receptor (EGFR) Correlates with disease relapse and progression to androgen— independence in human prostate cancer. CLINICAL CANCER RESEARCH, vol. 8, pag. 3438-3444
- Tortora G, Ciardiello F, Damiano V, De Laurentiis M, Matano E, Pepe S, De Placido S, Catalano G, Bianco AR. Preclinical and phase I study of Oxaliplatin and Topotecan in combination in human cancer. ANNALS OF ONCOLOGY, vol. 13, pag. 392-398
- Mustacchi G, Ceccherini R, Pluchinotta A, De Matteis A, Maiorino L, Farris A, Scanni A, De Placido S. Results of adjuvant treatment in breast cancer women aged more than 70: Italian cooperative group experience.. TUMORI, vol. 88, pag. S83-S85
- Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco AR, De Placido S. Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.. ONCOLOGY, vol. 63, pag. 219-225
- Ciardiello F, Tortora G, De Placido S, Bianco AR. ZD1839 (Iressa): preclinical studies and pharmacology.. TUMORI, vol. 88, pag. S155-S157,
- 2001 Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco Ar, Ciardiello F. Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. CLINICAL CANCER RESEARCH, vol. 7, pag. 2537-2544
- Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco Ar, Tortora G. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. CLINICAL CANCER RESEARCH, vol. 7, pag.
- Mosconi P, Colozza M, De Laurentiis M, De Placido S, Maltoni M. Survival, quality of life and breast cancer. BREAST CANCER RESEARCH AND TREATMENT, vol. 12, pag. 15-19
- 2000 Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco Ar, Mendelsohn J, G. Tortora. Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. CLINICAL CANCER RESEARCH, vol. 6, pag. 3739-3747

Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F. Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.. CLINICAL CANCER, vol. 6, pag. 4343-

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor.. CLINICAL CANCER RESEARCH, vol. 6, pag. 2053-2063

De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F, Bianco AR, Gallo C, Ricchi P, De Placido G, S Pignata, G. C. T. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. ANTICANCER RESEARCH, vol. 20, pag. 4023-4029

Pepe S, Ruggiero A, D'acquisto M, De Laurentiis M, De Placido S, Sandomenico C, Staibano S, De Rosa G, Lucariello A, D'armiento M, Bianco AR. Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. CANCER, vol. 89, pag. 1065-1075

Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production.. CLINICAL CANCER RESEARCH, vol. 6, pag. 2506-2512

Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A.. INTERNATIONAL JOURNAL OF CANCER, vol. 85, pag. 710-715

De Placido S, Lauria R, Perrone F, Vernaglia Lombardi A, Carlomagno C, Varriale E, Costanzo R, Leo L, De Laurentiis M, Bianco AR. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study.. ONCOLOGY, vol. 58, pag. 8-14

1999 De Laurentiis M, De Placido S, Bianco AR, Clark GM, Ravdin PM. A Prognostic Model that makes Quantitative Estimates of Probability of Relapse for Breast Cancer Patients. CLINICAL CANCER RESEARCH, vol. 5, pag. 4133-4139

Lauria R, Ferrari E, Tramontana S, Morabito A, Perrone F, Maffeo A, Fiorentino R, Casella G, Iodice F, Ricchi P, Carlomagno C, Varriale E, De Placido G, De Placido S, Bianco AR, Pignata S. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. ONCOLOGY, vol. 56, pag. 267-273

- Ciardello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.. CLINICAL CANCER RESEARCH, vol. 5, pag. 909-916
- De Placido S, Carlomagno C, Ciardiello F, De Laurentiis M, Pepe S, Ruggiero A, G. Tortora, Panico L, D' Antonio A, Pettinato G, Petrella G, Bianco AR. Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. CANCER RESEARCH, vol. 5, pag. 2854-2859
- De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.. INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, pag. 339-346
- 1998 De Placido S. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. HEPATOLOGY, vol. 28, pag. 751-755,
- Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo C, Monfardini S, Bianco AR. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.. JOURNAL OF CLINICAL ONCOLOGY, vol. 16, pag. 1414-16
- Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.. CLINICAL CANCER RESEARCH, vol. 4, pag. 241-249
- De Placido S . Tamoxifen in the treatment of hepatocellular carcinoma: a multicenter randomized controlled trial. LANCET, vol. 352, pag. 17-20
- De Placido S, Carlomagno C, De Laurentiis M, Bianco AR. C-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, vol. 52, pag. 55-64
- 1997 Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 89, pag. 881-886

- Pignata S, Lauria R, Perrone F, Ferrari E, Biondi E, Maffeo A, Morabito A, Graziano R, Carlomagno C, De Placido G, Gallo C, Bianco AR, Pergola M, De Placido S. Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer.. INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 11, pag. 175-180
- Bianco AR, Carlomagno C, De Laurentiis M, De Placido S, Tortora G, Ciardiello F. Prognostic factors in human colorectal cancer.. TUMORI, vol. 83, pag. S15-S18
- Costantini M, Mencaglia E, Di Giulio P, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Massidda B, Luzzani M, Campora E, De Placido S, Palmeri S, Palladino MA, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L.[Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project]. TUMORI, vol. 83, pag. S25-S27
- 1996 De Laurentiis M, Gallo C, De Placido S, Perrone F, Pettinato G, Petrella G, Carlomagno C, Panico L, Delrio P, Bianco AR. A predictive index of axillary nodal involvement in operable breast cancer.. BRITISH JOURNAL OF CANCER, vol. 73, pag. 1241-1247
- Caraglia M, Leardi A, Ricciardi B, De Laurentiis M, Lentini ML, Graziano, Matano E, De Placido S, Bianco AR, Tagliaferri P. A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.. INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 8, pag. 847-850,
- De Michele G, Perrone F, Filla A, Mirante E, Giordano M, De Placido S, Campanella G. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. NEUROLOGY, vol. 47, pag. 1260-1264
- Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, pag. 1770-1776
- Giordano L, Giorgi D, Fasolo G, Segnan N, Rosselli Del Turco M, Bianco AR, De Placido S, Sodano A, Pini MT, Nuzzo F, Perrone F. Breast cancer screening: characteristics and results of the Italian programmes in the Italian group for planning and evaluating breast cancer screening programmes (GISMa). TUMORI, vol. 82, pag. 31-37
- Panico L, D'Antonio A, Salvatore G, Mazza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Gullick WJ, Pettinato G, BiancoAR, Ciardiello F. Differential immunohistochemical detection of transforming growth factor α , amphiregulin and CRIPTO in human normal and malignant breast tissues.. INTERNATIONAL JOURNAL OF CANCER, vol. 65, pag. 51-56

Gridelli C, Perrone F, Palmeri S, D'aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). ANNALS OF ONCOLOGY, vol. 7, pag. 821-826,

Catalano L, Improta S, De Laurentiis M, Molica S, Majolino I, Musto P, Fragasso A, De Placido S, Rotoli B. Prognosis of chronic myelomonocytic leukemia. HAEMATOLOGICA, vol. 81, pag. 324-329

Perrone F, Carlomagno C, Lauria R, De Laurentiis M, Morabito A, Panico L, Pettinato G, G Petrella, Gallo C, Bianco AR, De Placido S. Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?. EUROPEAN JOURNAL OF CANCER, vol. 32A, pag. 41-46

Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco A R, De Placido S. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. JOURNAL OF CLINICAL ONCOLOGY, vol. 14, pag. 2702-2708,

1995 Perrone F, De Placido S, Gallo C, Carlomagno C, Lauria R, Bianco AR. Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile?. INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, pag. 1129-1137

De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Varriale E, Petrella G. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).. BRITISH JOURNAL OF CANCER, vol. 71, pag. 1283-1287

Pepe S, Ruggiero A, De Laurentiis M, Normanno N, Fiorentino B, Perrone F, Carlomagno C, De Placido S, Panico L, Pettinato G, Borriello G, Bianco AR. DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospective series of 515 primary breast cancer. ONCOLOGY REPORTS, vol. 2, pag. 345-359, ISSN: 1021-335X

Perrone F, Carlomagno C, De Placido S, Lauria R, Morabito A, Bianco AR. First-line systemic therapy for metastatic breast cancer and management of pleural effusion.. ANNALS OF ONCOLOGY, vol. 6, pag. 1033-1043

Gallo C, Perrone F, De Placido S . Informed versus randomised consent to clinical trial. LANCET, pag. 1060-1064

Tagliaferri P, Matano E, Rea A, Famiani M, Ciardiello F, Tortora G, Montesarchio V, Morabito A, Caraglia M, De Laurentiis M, De Placido S, Palmieri G, Bianco AR. Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-eligible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. . ONCOLOGY REPORTS, vol. 2, pag. 365-368

Carlomagno C, Perrone F, Lauria R, De Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A, Putrella G, Bianco AR, De Placido S. Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.. ONCOLOGY, vol. 52, pag. 272-277

De Placido S, Nuzzo F, Perrone F, Carlomagno C, Noviello A, Delrio P, Di Palma E, Pini MT, Cerato PL, Bianco C. The first breast cancer screening program in southern Italy: preliminary results from three municipalities of the Naples Province. TUMORI, vol. 81, pag. 7-12

Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, De Placido S. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. CANCER, vol. 76, pag. 1772-1778

Perrone F, De Placido S, Giusti C, Gallo C . [The request for consent in clinical research: a randomized study in healthy subjects]. EPIDEMIOLOGIA E PREVENZIONE, vol. 19, pag. 282-290

Gridelli C, Perrone F, D'Aprile M, Palmeri S, Lo Russo V, Palmieri G, De Placido S, Gallo C, Bianco AR .Phase II study of intensive CEV (carboplatino, epirubicina, and VP-16) plus G-CSF (Ggranulocyte-colony cell stimulatig factor) in extensive small cell lung cancer.. EUROPEAN JOURNAL OF CANCER, vol. 31a, pag. 2424-2426

1994 Gridelli C, Ianniello GP, Maiorino A, Curcio C, D'Aprile M, Brancaccio L, Palmeri S, Gentile M, Comella G, Pedicini T, Airoma G, Veltri E, Gebbia V, Russo A, Casaretti R, Giampaglia F, Ferrante G, Rausa L, Iacobelli S, Arcangeli G, De Placido S, Bianco AR.. Carboplatin, epirubicin and VP-16 chemotherapy in the treatment of small cell lung cancer.. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, vol. 17, pag. 160-162

Perrone F, S De Placido, Carlomagno C, Gravina A, De Laurentiis M, Del Mastro L, Gridelli C, Pagliarulo C, Bianco AR. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, vol. 17, pag. 218-222

Morabito A, Perrone F, Lauria R, Carlomagno C, Marinelli A, De Laurentiis M, Martignetti A, Pettinato G., Panico L, Petrella G, Gallo C, Bianco AR, De Placido S. Prognostic significance of multifocality in primary breast cancer.. ONCOLOGY REPORTS, pag. 1045-1048

- 1993 Perrone F, De Placido S, Carlomagno C, Nuzzo F, Ruggiero A, De Laurentiis M, Gridelli C, Pagliarulo C, Bianco AR. Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.. TUMORI, vol. 79, pag. 254-257
- Lorusso V, De Lena M, Lopez M, De Placido S, Vici P, Piano A, Palomba G, Carlomagno C, D'Aprile M, Fosser V, Brandi M, Bianco AR. Combination chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5-Fluorouracil versus CNF (Mitoxantrone, Fluorouracil, Cyclophosphamide) in advanced breast cancer. A multicenter randomized study.. INTERNATIONAL JOURNAL OF ONCOLOGY, pag. 531-535
- Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 698, pag. 330-338
- Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G, Bianco AR. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. EUROPEAN JOURNAL OF CANCER, vol. 29A, pag. 1729-1731
- 1991 Bianco AR, Rosso, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, Lenti R, V Fosser, De Placido S, Perrone F. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol. 12, pag. 429-437
- Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A, Incoronato P, De Placido S, Perrone F, Basilico L, Rausa L, Ferrante G, Bianco AR. Phase II study of mitomycin C, etoposide and vindesine (MEV) in metastatic, stage IV, non small cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 28, pag. 405-407, ISSN: 0344-5704
- Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol. 63, pag. 799-803
- Gridelli C, Contegiacomo A, Lauria R, Gentile M, Airoma G, De Placido S, Perrone F, Ferrante G, Bianco AR. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.. TUMORI, vol. 77, pag. 506-510
- 1990 Caponigro F, Iaffaioli V, Pagliarulo C, De Placido S, Frasci G, Ungaro B, Matano E, Bianco AR. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 5, pag. 73-76,

- De Placido S, Gallo C, Perrone F, Marinelli A, Pagliarulo C, Carlomagno C, Petrella G, D'Istria M, Delrio G, Bianco AR. Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.. BRITISH JOURNAL OF CANCER, vol. 62, pag. 643-646
- S De Placido, Gallo C, Marinelli A, Perrone F, Pagliarulo C, Petrella G, Delrio G, D'Istria M, Del Mastro L, Bianco AR. Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.. BREAST CANCER RESEARCH AND TREATMENT, vol. 16, pag. 111-117
- 1989 Lopez M, Contegiacomo A, Vici P, C Dello Iorio, Di Lauro L, Pagliarulo C, Carpano S, Giannarelli D, De Placido S, Fazio S.A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. CANCER, vol. 64, pag. 2431-2436
- Iaffaioli RV, Frasci G, Palmieri G, De Placido S, Mastrantonio P, Lombardi D, De Placido G, Montemagno U, Bianco AR. The adjuvant treatment of ovarian cancer: result of the pilot study of a new combination chemotherapeutic regimen (DAC). EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol. 10, pag. 349-352
- 1988 Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. LANCET, vol. 2, pag.1095-1099
- Iaffaioli R V, Bianchin A, Ruggiero G, Pirozzi G, Ungaro A, Totaro G, Gallo C, De Placido S, Pagliarulo C, Bianco AR. Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients.. ONCOLOGY, vol. 45, pag. 337-343
- 1987 Contegiacomo A, Fiorillo L, De Placido S, Pagliarulo C, Iaffaioli RV, Genua G, Giampaglia F, Palmieri G, Bianco AR. The treatment of metastatic pleural effusion in breast cancer: report of 25 cases.. TUMORI, vol. 73, pag. 611-617
- 1986 Delrio G, De Placido S, Pagliarulo C, D'Istria M, Fasano S, Marinelli A, Citarella F, De Sio L, Contegiacomo A, Iaffaioli RV. Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.. TUMORI, vol. 72, pag. 53-61
- 1985 Bianco AR, S De Placido, Pagliarulo C, Fasano S, D'Istria M, De Sio L, Ricciardi I, Delrio G. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.. CHEMIOTERAPIA, vol. 4, pag. 252-255
- 1978 Contieri E, Iodice R, Piscitelli L, Izzo R, De Placido S.[Association of gastric cancer and hepatitis. A theory to be verified]. MINERVA CHIRURGICA, vol. 33, pag. 1077-1080

Testi Universitari:

Autore del Manuale di Oncologia Medica edito dalla McGraw-Hill, "Core Curriculum-Oncologia Clinica" suggerito dalla maggior parte delle Università Italiane.

"F.to Sabino De Placido"